Key terms
About RARE
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RARE news
Mar 19
7:10am ET
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)
Mar 18
7:15am ET
JPMorgan ups Ultragenyx target, opens ‘Positive Catalyst Watch’ into data
Mar 14
6:50am ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Cannabist Company Holdings (OtherCBSTF)
Feb 27
8:40am ET
Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)
Feb 21
8:06am ET
Ultragenyx Pharmaceutical: A Strong Buy on Robust Crysvita Sales and Promising Pipeline Prospects
Feb 21
7:37am ET
Ultragenyx price target raised to $111 from $110 at TD Cowen
Feb 18
11:50pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 16
8:59am ET
Ultragenyx price target raised to $48 from $47 at Wedbush
Feb 16
8:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)
Feb 16
8:10am ET
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Disc Medicine (IRON) and Ultragenyx Pharmaceutical (RARE)
Feb 16
7:41am ET
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Nurix Therapeutics (NRIX) and AMN Healthcare Services (AMN)
Feb 16
6:58am ET
Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Feb 16
6:56am ET
Ultragenyx Pharmaceutical: A Strong Buy on Robust Growth and Pipeline Catalysts
Feb 16
6:35am ET
Ultragenyx Pharmaceutical’s Promising Clinical Trials Underpin Buy Rating
Feb 16
5:47am ET
Buy Rating Affirmed for Ultragenyx: A Bright Outlook on Regulatory Developments and Financial Stability
Feb 15
7:40pm ET
Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF), Pro Medicus Limited (OtherPMCUF) and Ultragenyx Pharmaceutical (RARE)
Feb 15
4:11pm ET
Ultragenyx sees FY24 revenue $500M-$530M, consensus $504.31M
Feb 15
4:09pm ET
Ultragenyx reports Q4 EPS ($1.52), consensus ($1.62)
Feb 08
7:45am ET
Buy Rating for Ultragenyx Pharmaceutical Amid Positive Gene Therapy Program Developments
Feb 07
8:37am ET
Buy Rating for Ultragenyx Pharmaceutical Backed by Promising Gene Therapy Study Results and FDA Engagement
Feb 07
6:25am ET
Ultragenyx Pharmaceutical: Strong Buy on Promising Gene Therapy Trial Results and Regulatory Prospects
Feb 06
8:10am ET
Ultragenyx announces data demonstrating treatment with UX111
Jan 30
6:33am ET
Ultragenyx pipeline undervalued ahead of 2024 catalysts, says Baird
Jan 29
6:31am ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Legend Biotech (LEGN) and Elevance Health (ELV)
Jan 25
7:20am ET
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Boston Scientific (BSX) and Ultragenyx Pharmaceutical (RARE)
Jan 17
7:41am ET
JPMorgan ups Ultragenyx target, adds to Analyst Focus List
Jan 15
2:28pm ET
Ultragenyx price target lowered to $124 from $131 at Stifel
Jan 11
1:28am ET
Ultragenyx Pharmaceutical: A Strong Buy on Robust Financials and Promising Pipeline
Jan 08
8:00am ET
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Ultragenyx Pharmaceutical (RARE) and Inspire Medical Systems (INSP)
Jan 08
7:59am ET
Mereo BioPharma provides update on pipeline progress, corporate developments
Jan 08
7:46am ET
Ultragenyx price target raised to $47 from $43 at Wedbush
No recent news articles are available for RARE
RARE Financials
Key terms
Ad Feedback
RARE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RARE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range